Holen Sie sich die Stockscreener-App
125.05
0.14%
0.18
Handel nachbörslich:
125.16
0.11
+0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$124.87
Offen:
$126.63
24-Stunden-Volumen:
8.01M
Relative Volume:
1.18
Marktkapitalisierung:
$155.26B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.01
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-1.71%
1M Leistung:
-6.93%
6M Leistung:
-0.11%
1J Leistung:
+17.76%
1-Tages-Spanne:
$124.44
$126.63
1-Wochen-Bereich:
$122.43
$128.20
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.05 | 153.66B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,107.08 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
239.08 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
234.76 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.60 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.38 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences highlights ongoing commitment to Pride, inclusion in community and workplace - ABC7 Bay Area
Gilead receives EU nod for Trodelvy in first-line metastatic triple-negative breast cancer - grafa.com
GILD Gains EU Approval for Trodelvy in Treating Triple-Negative Breast Cancer - GuruFocus
Gilead Sciences: The Market Is Underestimating Its Growth Runway (NASDAQ:GILD) - Seeking Alpha
Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com
Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment - marketscreener.com
Gilead Sciences draws Cantor support, shares sit below $155 target - AD HOC NEWS
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks - Investing.com Canada
Gilead Sciences wins FDA backing for weekly HIV pill, Cantor sticks to Overweight call on the shares - AD HOC NEWS
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Quiver Quantitative
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver? - Insider Monkey
Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 By Investing.com - Investing.com Canada
How Investors May Respond To Gilead Sciences (GILD) FDA Review Of Once‑Weekly Oral HIV PrEP - Sahm
Gilead Sciences (GILD) Gets a Buy from Scotiabank - The Globe and Mail
Gilead Sciences stock price forecast: $120.19 support in focus as GILD slides 1.82% - Traders Union
Gilead’s Work to Help End the HIV Epidemic, One Year after Launch of its Twice-Yearly Prevention Medication - Gilead Sciences
Vascular Dementia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare - Barchart.com
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Gilead Sciences Cell Therapy Move Draws Biotech Attention - Kalkine Media
Gilead Sciences StockFDA accepts filing for weekly HIV prevention pill - AD HOC NEWS
World Economic Forum, Takeda and Gilead executives confirmed for Women's HealthX in Boston - FemTech World
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Why Gilead Sciences bets on Sunlenca as a long-acting HIV anchor - AD HOC NEWS
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pharma Giants Navigate A Busy Deal-Making Backdrop - Kalkine Media
Gilead Sciences (GILD) Donates Remdesivir to Uganda - Yahoo Finance
Gilead Sciences Inc (GILD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voya Global High Dividend Low Volatility Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead Sciences (GILD) Receives a Buy from Citi - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD) - The Globe and Mail
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK - The Globe and Mail
Gilead Sciences chief comm officer sells $371k in stock - Investing.com UK
[Press release] FDA accepts Gilead’s application for investigational once-weekly oral Yeztugo, potentially the first long-acting pill for HIV prevention - European AIDS Treatment Group
Gilead Sciences chief comm officer sells $371k in stock By Investing.com - Investing.com Nigeria
Gilead (NASDAQ: GILD) officer sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Insider Sold Shares Worth $376,200, According to a Recent SEC Filing - marketscreener.com
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 trade - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention - Yahoo Finance UK
Gilead Sciences Stock (US3755581036): Quarterly earnings trends keep the biotech in focus - AD HOC NEWS
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Once-weekly HIV prevention push, Gilead’s Yeztugo tablet moves toward FDA review - AD HOC NEWS
Layoff Tracker: Neumora, enGene cut staff in cost-saving initiatives - BioSpace
Gilead Sciences (GILD) Seeks FDA Approval for Weekly HIV Prevention Pill - GuruFocus
GILD Receives FDA Acceptance for Yeztugo as HIV Preventative - GuruFocus
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
FDA accepts Gilead application for once-weekly oral HIV prevention pill - Investing.com Canada
Director sale notice: GILD (NASDAQ: GILD) files Form 144 for 9,000 shares - Stock Titan
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention - Business Wire
Morgan Stanley files Rule 144 for GILD common shares (GILD) - Stock Titan
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):